Rafferty Asset Management, LLC Allovir, Inc. Transaction History

Rafferty Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$6.75 - $13.52 $425,695 - $852,652	-63,066 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$12.94 - $25.99 $310,145 - $622,928	23,968 Added 61.3%	63,066 $816,000
Q3 2021 Nov 10, 2021	SELL	$16.97 - $25.06 $499,647 - $737,841	-29,443 Reduced 42.96%	39,098 $980,000
Q2 2021 Aug 10, 2021	SELL	$19.44 - $25.06 $116,717 - $150,460	-6,004 Reduced 8.05%	68,541 $1.35 Million
Q1 2021 May 10, 2021	BUY	$20.81 - $45.5 $1.41 Million - $3.08 Million	67,770 Added 1000.3%	74,545 $1.74 Million
Q4 2020 Feb 10, 2021	BUY	$23.94 - $46.81 $162,193 - $317,137	6,775 New	6,775 $260,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.